MSWA remains alert as we monitor the COVID-19 situation.
This article provides a current updates and useful links for further information.
Filter News Articles
02 December 2021
International Day of People with Disability 2021
MSWA Client Tracey Hockey’s philosophy to ‘never say never’ has seen her embrace every opportunity life has presented her with, including taking part in a cutting-edge stroke trial.
29 October 2021
NARNIA Communication App aiding language recovery after stroke
MSWA-funded researchers at Curtin University are developing a novel therapy approach for people with aphasia – a communication condition typically seen after stroke.
30 September 2021
MS medication ofatumumab now available under PBS
The Government has announced that ofatumumab (Kesimpta®) is now listed under the Pharmaceutical Benefit Scheme (PBS).
22 September 2021
New MSWA CEO appointed
The MSWA Board has announced the appointment of new CEO Melanie Kiely, who will replace Marcus Stafford AM when he steps down in October.
27 August 2021
Speech Pathologists giving Western Australians a voice
Speech Pathology plays a crucial role in helping people regain a fundamental part of being human – communication. Speech Pathologists study, assess, and treat changes in understanding language, speaking, reading, writing, and importantly, swallowing food and drink.
22 August 2021
New research and tools for speech pathology
Communication is a fundamental human right. Associate Professor Anne Whitworth from Curtin University is developing a new NARNIA Communication App to help people with communication issues after stroke. This is one of the newly funded projects from our record-breaking $10 million research contribution in 2021.
10 August 2021
Vale Dr Greg Brotherson
It is with sadness we advise that Dr Greg Brotherson passed away on Friday, 6 August 2021.
02 August 2021
“IT’S HUGE!” - MSWA Albany progress update, August 2021
Over her 25 years as a volunteer, employee and Client, Caroline Clarke-Smith has seen MSWA’s presence in Albany grow from a small support group to the development of a $7m facility for people living with neurological conditions.
22 July 2021
MS medication Aubagio (teriflunomide) delisted from Australian market
Aubagio (teriflunomide) a medication used to treat multiple sclerosis is being delisted in Australia by Sanfoli. Generic medications remain available.